American Century Companies Inc. Acquires Shares of 11,799 Assembly Biosciences, Inc. $ASMB

American Century Companies Inc. bought a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 11,799 shares of the biopharmaceutical company's stock, valued at approximately $113,000. American Century Companies Inc. owned approximately 0.15% of Assembly Biosciences as of its most recent filing with the Securities and Exchange Commission.

Separately, Man Group plc bought a new stake in shares of Assembly Biosciences during the 4th quarter worth approximately $309,000. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Stock Performance

ASMB traded up $0.18 during trading hours on Thursday, reaching $22.44. The company's stock had a trading volume of 56,729 shares, compared to its average volume of 48,472. Assembly Biosciences, Inc. has a 52 week low of $7.75 and a 52 week high of $27.17. The company's 50-day moving average is $21.61 and its 200-day moving average is $15.78. The firm has a market cap of $172.11 million, a PE ratio of -4.02 and a beta of 0.68.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, beating analysts' consensus estimates of ($1.73) by $0.40. Assembly Biosciences had a negative return on equity of 149.01% and a negative net margin of 117.20%.The business had revenue of $9.63 million for the quarter, compared to analysts' expectations of $5.30 million. Equities analysts anticipate that Assembly Biosciences, Inc. will post -6.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Zacks Research upgraded Assembly Biosciences to a "hold" rating in a research note on Tuesday, August 19th. Guggenheim upped their price objective on Assembly Biosciences from $31.00 to $39.00 and gave the stock a "buy" rating in a research note on Monday. Finally, HC Wainwright assumed coverage on Assembly Biosciences in a research note on Monday, August 18th. They set a "buy" rating and a $50.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $41.33.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.